Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring

Multiple sclerosis is a chronic demyelinating disease of the central nervous system (CNS) with an autoimmune component. Among the recent disease-modifying treatments available, Natalizumab, a monoclonal antibody directed against the alpha chain of the VLA-4 integrin (CD49d), is a potent inhibitor of...

Descripción completa

Detalles Bibliográficos
Autores principales: Khoy, Kathy, Mariotte, Delphine, Defer, Gilles, Petit, Gautier, Toutirais, Olivier, Le Mauff, Brigitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541830/
https://www.ncbi.nlm.nih.gov/pubmed/33072089
http://dx.doi.org/10.3389/fimmu.2020.549842

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541830/
https://www.ncbi.nlm.nih.gov/pubmed/33072089
http://dx.doi.org/10.3389/fimmu.2020.549842

Ejemplares similares